Naoto T Ueno

6395712, May 28, 2002

Mar 19, 1997

08/809021

Mien-Chie Hung - Houston TX
Naoto T. Ueno - Houston TX

Board of Regents, The University of Texas System - Austin TX

A01N 4302

514 44, 424649, 514449

The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185neu tyrosine kinase. Over-expression of the neu oncogene leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The inventors propose that E1A sensitizes cancer cells such that they become amenable to treatment by chemotherapeutic drugs.

7005424, Feb 28, 2006

Aug 31, 2001

09/943984

Mien-Chie Hung - Houston TX, US
Naoto T. Ueno - Houston TX, US

Board of Regents, The University of Texas System - Austin TX

A01N 43/04
A01N 63/00
A61K 31/70
A61K 9/27
A61K 48/00

514 44, 424 932, 424450

The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185neu tyrosine kinase. Over-expression of the neu oncogene leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The inventors propose that E1A sensitizes cancer cells such that they become amenable to treatment by chemotherapeutic drugs.

8021831, Sep 20, 2011

Aug 25, 2004

10/926409

Naoto T. Ueno - Houston TX, US
Hideki Ishihara - Hyogo, JP
Tamotsu Sudo - Kobe, JP
Tomoko Matsushima - Kobe, JP

Board of Regents, The University of Texas System - Austin TX
Sysmex Corporation - Kobe

C12Q 1/00
C12Q 1/68
G01N 33/53
G01N 33/567
G01N 33/574

435 4, 435 6, 435 71, 435 721, 435 723

The present invention provides a method for determining the chemosensitivity of a cancer cell to a taxane comprising assessing the effect of the taxane on the expression level or activity of one or more cell cycle molecules in a cancer cell. Such a method makes use of an automated analyzer system wherein cell cycle parameters (molecules) such as CDK1 kinase activity, CDK1 expression, CDK2 kinase activity, CDK2 expression, MAD2 expression, Cyclin B1, Cyclin E expression, p21 expression, and CDK6 expression; are assessed. The present invention further provides a method of obtaining a cell cycle profile of a cancer cell that is sensitive to a taxane.

20090233848, Sep 17, 2009

Mar 3, 2005

10/592276

Chandra Bartholomeusz - Houston TX, US
Naoto T. Ueno - Houston TX, US

A61K 38/16
C12N 15/64
A61P 35/00

514 12, 4353201

The present invention relates generally to the fields of cancer therapy and gene therapy. More particularly, the invention is directed to PEA15 as a treatment for cancer. In a particular embodiment, PEA15 acts as a tumor suppressor for treatment of the cancer. In another particular embodiment, the cancer cells comprises E1 tumor suppressor activity. In another embodiment, the tumorigenicity of the cells is associated with ERK-dependent transcription and proliferation. In a further embodiment, PEA15 facilitates sensitivity of a tumor cell to a chemotherapeutic, such as paclitaxel.

20120329061, Dec 27, 2012

Mar 11, 2011

13/583378

Michal Mego - Sturovo, SK
Sendurai Mani - Houston TX, US
Massimo Cristofanilli - Philadelphia PA, US
Naoto T. Ueno - Houston TX, US
James M. Reuben - Houston TX, US

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

C12Q 1/68

435 612

An assay and associated methodologies for detection of breast cancer are described. Circulating tumor cells (“CTCs”) undergo epithelial mesenchymal transition (“EMT”) prior to entering circulation, resulting in the loss of epithelial markers. These CTCs and EMT-related gene transcripts in the peripheral blood of patients are tested by quantitative RT-PCR to detect and diagnose breast cancer.